The age variation of HER2 immunohistochemistry positive rate in biopsy specimens of gastric cancer

Publication date: Available online 13 February 2020Source: Pathology - Research and PracticeAuthor(s): Yanfeng Xi, Chen Xu, Yiqiang Liu, Xiaochu Yan, Chuansheng Huang, Yueping Liu, Jinhong Mei, Zhe Wang, Bin Liu, Xiaoming Li, Wencai Li, Jianyun Lan, Peng Gao, Jifeng Wu, Jianming Zheng, Yingyong HouAbstractAimsThe aim of this study was to explore HER2 status and characteristics in biopsy specimens of gastric cancer (GC) in Chinese population.Methods and resultsA total of 27787 biopsy specimens of GC from 103 hospitals were obtained. Immunohistochemistry (IHC) staining of HER2 was performed. Overall HER2 IHC positive rate was 11.2%. HER2 positive rate elevated with the increase of age in total patients and both genders. The rates were 7.1%, 8.1%, 9.0%, 10.9%, 11.8%, 12.6%, and 12.1% when patient age was ≤30, 31-40, 41-50, 51-60, 61-70, 71-80, and>80, respectively (P 
Source: Pathology Research and Practice - Category: Pathology Source Type: research

Related Links:

(American Association for Cancer Research) A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types, according to results from a phase I study.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Conclusion PPLELC is uncommon but distinct subtype of NSCLC with unique clinicop athologic characteristics that tends to affect young nonsmoking patients, without significant predilection for sex and with strong association with Epstein-Barr virus (EBV) infection. Histology and immunohistochemistry are the main diagnostic methods. Rare or no driver gene mutations were found in t he common oncogenes such as EGFR mutations and ALK gene rearrangement, implying that the mutagenesis of these genes was not involved in the tumorigenesis of PPLELC. PD-1 and PD-L1 may be potential therapeutic targets for PPLELC. The patients a...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
This study examined the pharmacokinetics, absolute bioavailability, and tissue distribution of CNF2 in rats, and combined computer-aided technology to predict the druggability of CNF2. The binding site of CNF2 and the breast cancer target HER2 were examined with molecular docking technology. Next, ACD/Percepta software was used to predict the druggability of CNF2 based on the quantitative structure-activity relationship (QSAR). Finally, a simple and effective high-performance liquid chromatography (HPLC) method was used to determine plasma pharmacokinetics and tissue distribution of CNF2 in rats. Prediction and experimenta...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
CONCLUSIONS: MMR-D might result in shorter PFS with first-line chemotherapy for AGC. Subsequent anti-PD-1 therapy achieved higher ORR and longer PFS than prior chemotherapy in most MMR-D patients, supporting the earlier use of immune checkpoint inhibitors. PMID: 32156744 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
AbstractThe discovery of human epidermal growth factor receptor 2 (HER2) overexpression in 15 –20% of gastric adenocarcinomas has been a key advance in the global care of this disease. Validated by the ToGA trial in the first-line setting of advanced HER2-positive (+) gastric cancer (GC), trastuzumab, an anti-HER2 monoclonal antibody (mAb), was the first therapeutic agent to significantly improve the prognosis of these patients. Since these results, many attempts have been made to improve the clinical outcomes of patients with HER2+ GC. However, all the other HER2-targeting molecules have failed to show a survival be...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
ConclusionsWe developed the SPACiAL workflow to provide immunohistochemistry-guided in situ metabolomics on intact tissue sections. Diminishing the workload by automated recognition of histological and functional features, the pipeline allows comprehensive analyses of metabolic heterogeneity. The multimodality of immunohistochemical staining and extensive molecular information from imaging mass spectrometry has the advantage of increasing both the efficiency and precision for spatially resolved analyses of specific cell types. The SPACiAL method is a stepping stone for the objective analysis of high-throughput, multi-omics...
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
CONCLUSION: Our study shows that receiving lapatinib with food can increase its plasma concentration with no significantly increased drug-related toxicity. We suggest that a larger-sample-size clinical trial is needed to fully understand the effect of administration of lapatinib with food. PMID: 32058619 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
kami Trastuzumab, a monoclonal antibody to human epidermal growth factor receptor 2 (HER2), has improved survival in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (AGC). The inevitable development of resistance to trastuzumab remains a problem, however, with several treatment strategies that have proven effective in breast cancer having failed to show clinical benefit in AGC. In this review, we summarize the mechanisms underlying resistance to HER2-targeted therapy and outline past and current challenges in the treatment of HER2-positive AGC refractory to trastuzumab. We further descr...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Pathology | Study